Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vonoprazan Fumarate Injection for Peptic Ulcer Bleeding
NCT06783257Phase 2Not yet recruiting
- Sponsor
- Shandong New Time Pharmaceutical
- Start
- Feb 2025
- Primary completion
- Feb 2027
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial of Tavoniza in peptic ulcer disease (PUD) (3 arms), sponsored by Shandong New Time Pharmaceutical. Primary endpoint: Rebleeding rate within 72 hours. Planned start Feb 2025; status: not yet recruiting.
02
Drugs
Tavoniza
03
Conditions
peptic ulcer disease (PUD)
Beyond the preview
Go deeper on NCT06783257.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06783257.